MJBizDaily Reports Medical Cannabis Authorizers Up 16%

What MJBizDaily reported, and what it didn't say

The one hard number in the report is a 16% increase in medical cannabis authorizers, and MJBizDaily framed it for operators.

Its headline put the figure at 16%. The summary available to CannIntel doesn't specify the jurisdiction, the measurement period, or the baseline count. We won't guess at any of them.

Those gaps matter. A 16% rise off a small base is a rounding error. Off a large base, it's a demand signal. Anyone modeling from this should pull the underlying dataset from MJBizDaily first.

Why authorizer counts drive patient demand

Authorizers sit at the top of the medical funnel, so their growth tends to precede patient and sales growth rather than follow it.

These are the clinicians who can certify or recommend cannabis for a patient. In practice the chain runs like this:

1. More authorizers are on the books.
2. More patient certifications and renewals get issued.
3. Dispensary traffic and basket sizes rise.
4. Wholesale orders follow, and cultivators adjust production plans.

The lag varies by market. Not every authorizer is active, either. A name on a registry isn't a patient seen.

The operator read: where 16% helps and where it doesn't

More authorizers widen access, but operators capture the gain only if new clinicians certify patients who then buy in licensed channels.

Headcount without throughput is a vanity metric. Operators should check the following before reading the number as good news:

• What share of new authorizers have certified at least one patient.
• Whether certification volume and active patient counts rose alongside the 16%.
• Whether new patients are skewing toward lower-priced products, which would pressure margins.
• Whether adult-use sales in the same market are pulling patients out of the medical channel.

That last point is the quiet risk. Where adult-use is legal, the medical card is a tax and potency play, and a larger authorizer pool doesn't guarantee more cardholders.

The Latin American parallel

In Brazil and Colombia, prescriber supply is a clear bottleneck for medical demand, which is why a headline like this one travels.

Brazil's ANVISA oversees prescription cannabis products, and a patient needs a receita from a physician to get one. The number of prescritores willing to write that receita sets the ceiling on the legal market, and because Brazil's supply leans heavily on imported finished product, every new prescriber pulls on foreign producers.

Colombia sits on the other side of that trade. Colombia's Law 1787 of 2016 created its medical framework and a licensed cultivation base that looks outward for demand. For Colombian producers, a rising prescriber count anywhere is a reason to keep export capacity.

The U.S. link is indirect. Federal law bars cannabis imports, so growth in U.S. authorizers feeds domestic cultivators, not Latin American exporters. What does cross borders is capital and product strategy. Multistate operators and export-minded producers read these prescriber and authorizer trends when they decide where to put money.

What to watch next

Three data points will show whether the 16% is a real demand signal: active patient counts, certification volume, and monthly medical sales.

For full background on this story and related coverage, see the CannIntel topic hub on the medical cannabis patient market.

• Active patient registrations in the same jurisdiction and period.
• Certification and renewal volume per authorizer.
• Medical-only sales, separated from adult-use where both exist.

The next signal is the regulator's next patient-count release. If patients don't move with authorizers, the 16% is a paperwork story, not a revenue one.